Bioventus (BVS) to Release Quarterly Earnings on Thursday

Bioventus (NYSE:BVSGet Rating) will be issuing its quarterly earnings data before the market opens on Thursday, August 11th. Analysts expect the company to announce earnings of $0.14 per share for the quarter. Parties interested in registering for the company’s conference call can do so using this link.

Bioventus (NYSE:BVSGet Rating) last issued its quarterly earnings data on Tuesday, May 10th. The company reported $0.04 EPS for the quarter, topping analysts’ consensus estimates of $0.01 by $0.03. Bioventus had a negative net margin of 5.29% and a positive return on equity of 12.58%. The firm had revenue of $117.29 million for the quarter, compared to analyst estimates of $118.09 million. During the same quarter in the previous year, the business posted ($0.02) EPS. On average, analysts expect Bioventus to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Bioventus Stock Performance

Shares of BVS stock opened at $8.73 on Thursday. Bioventus has a 12 month low of $6.30 and a 12 month high of $17.53. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.43 and a quick ratio of 1.05. The firm has a market capitalization of $673.49 million, a P/E ratio of -26.45 and a beta of 2.07. The company’s fifty day moving average price is $8.34 and its two-hundred day moving average price is $10.93.

Hedge Funds Weigh In On Bioventus

Institutional investors have recently added to or reduced their stakes in the company. Lazard Asset Management LLC raised its stake in shares of Bioventus by 123.9% in the 1st quarter. Lazard Asset Management LLC now owns 3,132 shares of the company’s stock valued at $44,000 after purchasing an additional 1,733 shares in the last quarter. HighTower Advisors LLC raised its stake in Bioventus by 15.5% during the first quarter. HighTower Advisors LLC now owns 14,965 shares of the company’s stock worth $211,000 after acquiring an additional 2,007 shares during the period. PNC Financial Services Group Inc. lifted its holdings in Bioventus by 1,845.5% in the first quarter. PNC Financial Services Group Inc. now owns 2,140 shares of the company’s stock worth $30,000 after acquiring an additional 2,030 shares during the last quarter. Salem Investment Counselors Inc. lifted its holdings in Bioventus by 1.5% in the first quarter. Salem Investment Counselors Inc. now owns 235,145 shares of the company’s stock worth $3,316,000 after acquiring an additional 3,490 shares during the last quarter. Finally, Mariner LLC lifted its holdings in Bioventus by 14.8% in the first quarter. Mariner LLC now owns 28,017 shares of the company’s stock worth $395,000 after acquiring an additional 3,613 shares during the last quarter. Institutional investors and hedge funds own 86.85% of the company’s stock.

Bioventus Company Profile

(Get Rating)

Bioventus Inc a medical device company, focuses on developing and commercializing clinical treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral nerve stimulation products.

Featured Articles

Earnings History for Bioventus (NYSE:BVS)

Want More Great Investing Ideas?

Receive News & Ratings for Bioventus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioventus and related companies with MarketBeat.com's FREE daily email newsletter.